XTRA:BIO3

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. More Details


Snowflake Analysis

Overvalued with concerning outlook.


Similar Companies

Share Price & News

How has Biotest's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BIO3 is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: BIO3's weekly volatility (5%) has been stable over the past year.


Market Performance


7 Day Return

1.5%

BIO3

2.1%

DE Biotechs

1.4%

DE Market


1 Year Return

21.9%

BIO3

-7.1%

DE Biotechs

0.9%

DE Market

Return vs Industry: BIO3 exceeded the German Biotechs industry which returned -7.1% over the past year.

Return vs Market: BIO3 exceeded the German Market which returned 0.9% over the past year.


Shareholder returns

BIO3IndustryMarket
7 Day1.5%2.1%1.4%
30 Day0%2.9%8.7%
90 Day2.3%-7.4%2.3%
1 Year22.2%21.9%-7.0%-7.1%4.1%0.9%
3 Year32.6%31.8%4.5%3.7%3.9%-5.1%
5 Year79.8%77.8%49.7%48.1%24.8%7.1%

Long-Term Price Volatility Vs. Market

How volatile is Biotest's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Biotest undervalued compared to its fair value and its price relative to the market?

2.3x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: BIO3 (€26.4) is trading above our estimate of fair value (€19.45)

Significantly Below Fair Value: BIO3 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: BIO3 is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.

PE vs Market: BIO3 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BIO3's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BIO3 is good value based on its PB Ratio (2.3x) compared to the DE Biotechs industry average (3.7x).


Next Steps

Future Growth

How is Biotest forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

54.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BIO3 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BIO3 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BIO3 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BIO3's revenue (8.7% per year) is forecast to grow faster than the German market (5.8% per year).

High Growth Revenue: BIO3's revenue (8.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BIO3's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Biotest performed over the past 5 years?

-21.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BIO3 is currently unprofitable.

Growing Profit Margin: BIO3 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BIO3 is unprofitable, and losses have increased over the past 5 years at a rate of 21.9% per year.

Accelerating Growth: Unable to compare BIO3's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BIO3 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11.2%).


Return on Equity

High ROE: BIO3 has a negative Return on Equity (-7.56%), as it is currently unprofitable.


Next Steps

Financial Health

How is Biotest's financial position?


Financial Position Analysis

Short Term Liabilities: BIO3's short term assets (€542.2M) exceed its short term liabilities (€103.3M).

Long Term Liabilities: BIO3's short term assets (€542.2M) do not cover its long term liabilities (€574.7M).


Debt to Equity History and Analysis

Debt Level: BIO3's debt to equity ratio (98.3%) is considered high.

Reducing Debt: BIO3's debt to equity ratio has increased from 87.1% to 98.3% over the past 5 years.

Debt Coverage: BIO3's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if BIO3's interest payments on its debt are well covered by EBIT.


Balance Sheet


Next Steps

Dividend

What is Biotest current dividend yield, its reliability and sustainability?

0.15%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: BIO3's dividend (0.15%) isn’t notable compared to the bottom 25% of dividend payers in the German market (1.14%).

High Dividend: BIO3's dividend (0.15%) is low compared to the top 25% of dividend payers in the German market (3.66%).


Stability and Growth of Payments

Stable Dividend: BIO3 is not paying a notable dividend for the German market, therefore no need to check if payments are stable.

Growing Dividend: BIO3 is not paying a notable dividend for the German market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: BIO3 is not paying a notable dividend for the German market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BIO3's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.3yrs

Average management tenure


CEO

Michael Ramroth (59 yo)

1.5yrs

Tenure

€1,276,000

Compensation

Dr. Michael Ramroth serves as Chairman of the Management Board and CEO at Biotest Aktiengesellschaft since May 01, 2019. Dr. Ramroth serves as Chief Financial Officer at Biotest Aktiengesellschaft. He serv...


CEO Compensation Analysis

Compensation vs Market: Michael's total compensation ($USD1.53M) is about average for companies of similar size in the German market ($USD1.56M).

Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Michael Ramroth
Chairman of the Management Board1.5yrs€1.28mno data
Georg Floß
COO & Member of the Board of Management7.83yrs€1.03mno data
Monika Buttkereit
Head of Investor Relationsno datano datano data
Christina Erb
Head of Corporate HR5.25yrsno datano data
Katrin Bernöster
Head of the Project Management Organisationno datano datano data
Peter Seith
Head of Quality Operationsno datano datano data
Jörg Schüttrumpf
Head of Research & Developmentno datano datano data
Wolfgang Möller
Head of Development - Plasma Proteinno datano datano data
Hermann Keuper
Senior Vice President of Manufacturingno datano datano data

5.3yrs

Average Tenure

Experienced Management: BIO3's management team is seasoned and experienced (5.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Xiaoying Gao
Member of Supervisory Board0.50yrno datano data
Kerstin Birkhahn
Member of Supervisory Board10.58yrs€44.00kno data
Rolf Hoffmann
Chairman of the Supervisory Board3.25yrs€135.00kno data
Jurgen Heilmann
Member of Supervisory Board9.17yrs€44.00kno data
Tan Yang
Deputy Chairman of Supervisory Board2.67yrs€72.00kno data
Simone Fischer
Member of Supervisory Board0.75yrno datano data

3.0yrs

Average Tenure

61yo

Average Age

Experienced Board: BIO3's board of directors are not considered experienced ( 3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Biotest Aktiengesellschaft's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Biotest Aktiengesellschaft
  • Ticker: BIO3
  • Exchange: XTRA
  • Founded: 1946
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €1.053b
  • Shares outstanding: 39.57m
  • Website: https://www.biotest.com

Number of Employees


Location

  • Biotest Aktiengesellschaft
  • Landsteinerstrasse 5
  • Dreieich
  • Hessen
  • 63303
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BIO3DB (Deutsche Boerse AG)YesPreference SharesDEEURJan 1992
BIO3XTRA (XETRA Trading Platform)YesPreference SharesDEEURJan 1992
0N70LSE (London Stock Exchange)YesPreference SharesGBEURJan 1992
BIES.FOTCPK (Pink Sheets LLC)YesPreference SharesUSUSDJan 1992
BIO3DBATS-CHIXE (BATS 'Chi-X Europe')YesPreference SharesGBEURJan 1992
BIO3SWX (SIX Swiss Exchange)YesPreference SharesCHCHFJan 1992
BIO3WBAG (Wiener Boerse AG)YesPreference SharesATEURJan 1992
BIODB (Deutsche Boerse AG)Ordinary SharesDEEURJun 1996
BIOXTRA (XETRA Trading Platform)Ordinary SharesDEEURJun 1996
0N6ZLSE (London Stock Exchange)Ordinary SharesGBEURJun 1996
BIODBATS-CHIXE (BATS 'Chi-X Europe')Ordinary SharesGBEURJun 1996

Biography

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through Therapy, Plasma & Services, and Othe...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/27 18:53
End of Day Share Price2020/11/27 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.